Last reviewed · How we verify
early HAART
early HAART is a Small molecule drug developed by Hospital Nossa Senhora da Conceicao. It is currently FDA-approved.
Early HAART, marketed by Hospital Nossa Senhora da Conceicao, is an established treatment in the antiretroviral therapy market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market position. However, the lack of specified primary indication and revenue data poses a significant risk in assessing its competitive landscape and financial performance.
At a glance
| Generic name | early HAART |
|---|---|
| Sponsor | Hospital Nossa Senhora da Conceicao |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals (PHASE1)
- Strategic Timing of Antiretroviral Treatment (PHASE4)
- Anti-HIV Medications for People Recently Infected With HIV (PHASE4)
- Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART) (NA)
- Early Antiviral Therapy for Critically Ill HIV Infected Patients (PHASE4)
- Functional Cure Study of HIV-infected Patients (NA)
- Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial) (PHASE1)
- Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- early HAART CI brief — competitive landscape report
- early HAART updates RSS · CI watch RSS
- Hospital Nossa Senhora da Conceicao portfolio CI
Frequently asked questions about early HAART
What is early HAART?
Who makes early HAART?
What development phase is early HAART in?
Related
- Manufacturer: Hospital Nossa Senhora da Conceicao — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing